NextCure, Inc.
NXTC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001661059
In the last 90 days, NextCure, Inc. insiders filed 2 open-market purchases and 1 sale; 30 institutions reported holding it in 13F filings for Q2 2026, worth $2.78M in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in NextCure, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 24
- +7 vs. Q3 2025
- Shares held
- 1.90M
- +1.04M (+121.1%) vs. Q3 2025
- Total value
- $26.9M
- +$21.9M (+435.7%) vs. Q3 2025
- New holders
- 9
- 5 more added
- Sold out
- 2
- 3 more reduced
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NXTC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 30 | $2.78M |
| Q1 2026 | 26 | $23.0M |
| Q4 2025 | 24 | $26.9M |
| Q3 2025 | 17 | $5.03M |
| Q2 2025 | 30 | $5.65M |
| Q1 2025 | 38 | $7.38M |
| Q4 2024 | 46 | $13.1M |
| Q3 2024 | 44 | $21.7M |
| Q2 2024 | 49 | $25.5M |
| Q1 2024 | 47 | $36.0M |
| Q4 2023 | 43 | $15.3M |
| Q3 2023 | 41 | $16.6M |
| Q2 2023 | 43 | $24.0M |
| Q1 2023 | 44 | $19.6M |
| Q4 2022 | 45 | $18.9M |
| Q3 2022 | 52 | $41.8M |
| Q2 2022 | 51 | $67.9M |
| Q1 2022 | 59 | $64.3M |
| Q4 2021 | 71 | $86.2M |
| Q3 2021 | 71 | $99.5M |
| Q2 2021 | 78 | $124.2M |
| Q1 2021 | 92 | $179.8M |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding NextCure, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BNP Paribas Arbitrage, SA | 32 | $454 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 61 | $866 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 66 | $937 | 0.00% | +66 | New |
| Bank of America Corp | 173 | $2.45K | 0.00% | +150+652.2% | Added |
| UBS Group AG | 338 | $4.80K | 0.00% | −263−43.8% | Reduced |
| Barclays PLC | 5,626 | $79.8K | 0.00% | 00.0% | Unchanged |
| Sio Capital Management, LLC | 10,940 | $155.2K | 0.03% | 00.0% | Unchanged |
| Marshall Wace, LLP | 11,292 | $160.2K | 0.00% | +11,292 | New |
| Millennium Management LLC | 13,033 | $184.9K | 0.00% | +13,033 | New |
| Cardiff Park Advisors, LLC | 21,833 | $309.8K | 0.03% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 23,157 | $328.7K | 0.00% | +3,636+18.6% | Added |
| Acadian Asset Management LLC | 26,765 | $379.0K | 0.00% | −9,910−27.0% | Reduced |
| BlackRock, Inc. | 27,793 | $394.4K | 0.00% | −3,293−10.6% | Reduced |
| Renaissance Technologies LLC | 33,634 | $477.3K | 0.00% | +5,300+18.7% | Added |
| Boothbay Fund Management, LLC | 69,617 | $987.9K | 0.03% | +69,617 | New |
| Vanguard Group Inc | 91,910 | $1.30M | 0.00% | +23,927+35.2% | Added |
| AWM Investment Company, Inc. | 117,371 | $1.67M | 0.16% | +117,371 | New |
| Pfizer Inc | 157,646 | $2.24M | 0.95% | 00.0% | Unchanged |
| Exome Asset Management LLC | 165,000 | $2.34M | 1.16% | +165,000 | New |
| Silverarc Capital Management, LLC | 176,057 | $2.50M | 0.36% | +176,057 | New |
| Sofinnova Investments, Inc. | 222,654 | $3.16M | 0.14% | 00.0% | Unchanged |
| Squadron Capital Management LLC | 236,966 | $3.36M | 1.50% | +236,966 | New |
| Ikarian Capital, LLC | 238,303 | $3.38M | 0.44% | +238,303 | New |
| Affinity Asset Advisors, LLC | 247,294 | $3.51M | 0.25% | +55,412+28.9% | Added |
| Cable Car Capital LLC | 0 | $0 | 0.00% | −63,178−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −1−100.0% | Sold out |